Italy Lung Cancer Therapeutics Market Report 2022 to 2030

Italy Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Italy Lung Cancer Therapeutics Market will reach a value of $1286 Mn from $715 Mn in 2022, growing at a CAGR of 7.6% during 2022-2030. The Lung Cancer Therapeutics Market in Italy is dominated by a few domestic pharmaceutical companies such as Menarini, Chiesi, and MolMed. The Lung Cancer Therapeutics Market in Italy is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Italy lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10ITPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Italy AUTHOR: Dr. Vishwa Modhia

Buy Now

Italy Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Italy Lung Cancer Therapeutics market will reach a value of $1286 Mn from $715 Mn in 2022, growing at a CAGR of 7.6% during 2022-2030.

Italy is a high-income, developed country located in Southern Europe comprising the boot-shaped Italian peninsula and several islands including Sicily and Sardinia. According to the Italian Association of Medical Oncology (AIOM) and the Italian Association of Tumour Registries, there were approximately 41,500 new cases and 33,836 deaths from lung cancer in Italy in 2018, with a 5-year survival rate of 16% and a 10-year survival rate of 12%. Lung cancer is a major issue in Italian clinical research, with around 80 active phases II, III, and/or IV studies, as well as over 30 phase I early clinical trials, currently recruiting patients with lung cancer.

Italy is one of the countries with the highest number of thoracic surgery units equipped with a robotic system. Currently, robotic-assisted interventions are performed at 27 Italian thoracic surgical centres. According to the latest WHO data published in 2020 Lung Cancers Deaths in Italy reached 34,152 or 6.29% of total deaths. The age-adjusted Death Rate is 21.68 per 100,000 population ranks Italy 42^nd in the world. Italy's government spends 9.6 % of its GDP on healthcare.

Italy Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

Italy is one of the countries with the highest number of thoracic surgery units equipped with a robotic system. Currently, robotic-assisted interventions are performed at 27 Italian thoracic surgical centres. The third-generation EGFR tyrosine kinase inhibitor (TKI) osimertinib has been approved for clinical use in Italy since September 2018, making it the therapy of choice for EGFR-positive, advanced NSCLC. Italy has always been a pioneering workshop for minimally invasive surgery, particularly in the thoracic surgery domain, determining the spread of minimally invasive procedures for lung cancer (as video-assisted thoracic surgery [VATS] and robotic-assisted thoracic surgery [RATS]) throughout all Italian regions.

Tobacco use is the leading cause of lung cancer in Italy, accounting for 85 to 90 % of cases. In Italy, the industrial sector is still highly regarded. These aspects could boost Italy's Lung Cancer Therapeutics market.

Market Restraints

Due to reimbursement issues, several centres continue to use a sequential strategy characterised using first or second-generation TKIs initially followed by osimertinib at the time of systemic disease progression in the case of T790M positivity based on cell-free DNA or tumour tissue genotyping. Despite the fact that Italy is a developed country with a strong healthcare system, financing for specialised research efforts is limited. This can make it challenging to get the necessary funds for research and development of new liver cancer treatments. These factors may deter new entrants into the Italy Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Menarini: Menarini is an Italian pharmaceutical company that produces several drugs for the treatment of lung cancer, including Alimta and Iressa
Bristol Myers Squibb (BMS): BMS is an American multinational pharmaceutical company that has a significant presence in Italy and produces several drugs for the treatment of lung cancer, including Opdivo and Yervoy
Chiesi: Chiesi is an Italian pharmaceutical company that produces several drugs for the treatment of cancer, including lung cancer
MolMed: MolMed is an Italian biotechnology company that is focused on the development of targeted immunotherapies for the treatment of cancer, including lung cancer
Philogen: Philogen is an Italian biotechnology company that is focused on the development of immunotherapies for the treatment of cancer, including lung cancer

Healthcare Policies and Reimbursement Scenarios

Several agencies, notably the Italian Medicines Agency (AIFA), the National Institute of Health (ISS), and the Italian healthcare system regulate and reimburse lung cancer therapies in Italy. AIFA oversees regulating and approving lung cancer medicines in Italy. The reimbursement of lung cancer medicines is based on the Italian Medicines Agency and the National Institute of Health's review (ISS). Furthermore, some lung cancer medicines may be provided through specific programmes inside the Italian healthcare system, such as the National Plan for Clinical Governance of Oncology, which offers to fund for cancer treatments that are not generally available.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.